tretinoin and Musculoskeletal-Diseases

Arsenic trioxide has recently been introduced as a promising new agent to treat refractory acute promyelocytic leukemia (APL). In the present study, arsenic trioxide was given intravenously for 42 days to a 56-year-old female patient suffering from chemotherapy/ATRA-resistant APL, with 43% APL blasts in the bone marrow and elevated D-dimers. During the first days of arsenic trioxide treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes. This initial coagulation response was followed by a second phase of hematological response (starting on days 15-20) characterized by leukocytosis, occurrence of myeloid progenitor cells in the peripheral blood, and a decrease in bone marrow blasts (<1% on days 28 and 36). Finally, the patient entered complete hematological and cytogenetic remission, although the PML-RAR alpha fusion product was still detectable by PCR. These data confirm the therapeutic value of arsenic trioxide in relapsed/resistant APL.

Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromosome Banding; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Feeding and Eating Disorders; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Metaphase; Middle Aged; Musculoskeletal Diseases; Oxides; Pain; Polymerase Chain Reaction; Recurrence; Tretinoin

Topics: Acne Vulgaris; Administration, Topical; Adolescent; Erythromycin; Humans; Male; Musculoskeletal Diseases; Radiography; Tretinoin